SciTech Development raised $5.5 million to advance ST-001 nanoFenretinide, an FDA-designated orphan drug in clinical trials for the treatment of T-cell non-Hodgkin lymphoma, a rare and aggressive blood cancer.
SciTech Development raised $5.5 million to advance ST-001 nanoFenretinide, an FDA-designated orphan drug in clinical trials for the treatment of T-cell non-Hodgkin lymphoma, a rare and aggressive blood cancer.